PL3522871T3 - Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki - Google Patents

Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki

Info

Publication number
PL3522871T3
PL3522871T3 PL17798019T PL17798019T PL3522871T3 PL 3522871 T3 PL3522871 T3 PL 3522871T3 PL 17798019 T PL17798019 T PL 17798019T PL 17798019 T PL17798019 T PL 17798019T PL 3522871 T3 PL3522871 T3 PL 3522871T3
Authority
PL
Poland
Prior art keywords
protozoa
provide stable
live vaccines
lyophilization methods
stable dehydrated
Prior art date
Application number
PL17798019T
Other languages
English (en)
Inventor
Rim Daoussi
Frederick H. Weber
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PL3522871T3 publication Critical patent/PL3522871T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17798019T 2016-10-05 2017-10-04 Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki PL3522871T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404448P 2016-10-05 2016-10-05
EP17798019.0A EP3522871B1 (en) 2016-10-05 2017-10-04 Lyophilization methods that provide stably dehydrated protozoans for use as potent live vaccines
PCT/US2017/055056 WO2018067647A1 (en) 2016-10-05 2017-10-04 Lyophilization methods that provide stably dehydrated protozoans for use as potent live vaccines

Publications (1)

Publication Number Publication Date
PL3522871T3 true PL3522871T3 (pl) 2022-02-14

Family

ID=60327367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17798019T PL3522871T3 (pl) 2016-10-05 2017-10-04 Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki

Country Status (15)

Country Link
US (1) US11453854B2 (pl)
EP (1) EP3522871B1 (pl)
JP (2) JP2019533995A (pl)
CN (1) CN109789097B (pl)
AU (1) AU2017339971B2 (pl)
CA (1) CA3037544C (pl)
ES (1) ES2903260T3 (pl)
HU (1) HUE057035T2 (pl)
MX (1) MX2019003947A (pl)
NZ (1) NZ752142A (pl)
PL (1) PL3522871T3 (pl)
PT (1) PT3522871T (pl)
UA (1) UA125029C2 (pl)
WO (1) WO2018067647A1 (pl)
ZA (1) ZA201901900B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109370908A (zh) * 2018-11-16 2019-02-22 中农威特生物科技股份有限公司 一种鸡球虫卵囊的培养和保存液及其应用
CN111234035A (zh) * 2020-02-13 2020-06-05 北京海木集团有限公司 一种融合蛋白及一种犬弓形虫亚单位疫苗及其疫苗组合物
CN114965998B (zh) * 2022-06-01 2025-04-11 山东省寄生虫病防治研究所 一种基于新型长效抗原TGIMP1C的弓形虫抗体IgG酶联免疫检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3783098A (en) 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US3915794A (en) 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US4000256A (en) 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4672037A (en) * 1983-11-03 1987-06-09 American Type Culture Collection Method of culturing freeze-dried microorganisms
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5707617A (en) 1994-03-21 1998-01-13 The Regents Of The University Of California Bovine neospora isolates
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
GB9505523D0 (en) * 1995-03-18 1995-05-03 Wellcome Found Lyophilization process
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
EP0841392B1 (en) 1996-11-12 2004-07-14 Pfizer Inc. Attenuated live neospora vaccine
US5856172A (en) * 1997-01-03 1999-01-05 Quality Technologies, Llc Preservation of microorganisms in a vial with a cap comprising an immobilized desiccant
BR9803232A (pt) 1997-08-26 2000-01-11 Pfizer Prod Inc Vaicna de neospora.
KR20010024245A (ko) * 1997-10-20 2001-03-26 조지 제이. 리코스 네오스포라 백신
US20040131633A1 (en) 1999-04-21 2004-07-08 University Of Technology, Sydney Parasite antigens
AUPQ905600A0 (en) 2000-07-28 2000-08-24 Insearch Limited Parasites
HRP20090271A2 (en) 2002-08-26 2009-11-30 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
US7935478B2 (en) * 2004-02-02 2011-05-03 Core Dynamics Limited Biological material and methods and solutions for preservation thereof
US8793895B2 (en) 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
ES2326770B1 (es) 2007-07-13 2010-07-26 Universidad Complutense De Madrid Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora.
TWI436789B (zh) 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
AU2009283216B2 (en) * 2008-08-20 2015-04-02 Celularity Inc. Improved cell composition and methods of making the same
WO2011101796A1 (en) 2010-02-19 2011-08-25 Cadila Pharmaceuticals Limited A pharmaceutical composition of killed cells with substantially retained immunogenicity
CN102511471B (zh) * 2011-12-15 2013-08-28 成都清科生物科技有限公司 一种间充质干细胞冻存液及其制备方法
CN103299986A (zh) * 2013-07-03 2013-09-18 中山大学 一种寄生原虫冻干粉及其制备方法
US10632182B2 (en) 2014-05-14 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Methods for freeze-drying and rehydrating biologics

Also Published As

Publication number Publication date
CA3037544A1 (en) 2018-04-12
NZ752142A (en) 2026-01-30
CN109789097A (zh) 2019-05-21
EP3522871B1 (en) 2021-11-17
HUE057035T2 (hu) 2022-04-28
ZA201901900B (en) 2025-07-30
US11453854B2 (en) 2022-09-27
BR112019006900A2 (pt) 2019-07-02
US20210284950A1 (en) 2021-09-16
AU2017339971A1 (en) 2019-04-11
WO2018067647A1 (en) 2018-04-12
PT3522871T (pt) 2022-01-05
CA3037544C (en) 2021-10-12
JP2019533995A (ja) 2019-11-28
JP7554729B2 (ja) 2024-09-20
JP2022017261A (ja) 2022-01-25
MX2019003947A (es) 2019-06-10
CN109789097B (zh) 2021-05-18
AU2017339971B2 (en) 2023-03-02
EP3522871A1 (en) 2019-08-14
ES2903260T3 (es) 2022-03-31
UA125029C2 (uk) 2021-12-29

Similar Documents

Publication Publication Date Title
IL261271A (en) Methods for making l-glufosinate
IL264454A (en) Novel compositions, uses and methods for making them
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
DK3393510T3 (da) Zikavirusvaccine
DK3778903T3 (da) Trisegmenterede arenavira som vaccinevektorer
HUE051862T2 (hu) Stabil, IFNAR1-elleni készítmény
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
LT3240895T (lt) Kompozicijos ir būdai, skirti baltymų glikozilinimui
LT3102123T (lt) Galūnės turniketas
EP3525751A4 (en) HIGH IMPACT AND HIGH PERFORMANCE FLOWER PAIRING
DK3303704T3 (da) Kunstgræsbanesystem
EP3140761C0 (en) INTELLIGENT SERVICE ASSISTANT - INSTRUMENT SIDE SOFTWARE CLIENT
PL3310340T3 (pl) Formulacje o wysokim stężeniu
DK3292180T3 (da) Formuleringer til forbedret olieudvinding, der omfatter sulfonater
EP3367997A4 (en) Novel occlusive formulations
IL256833A (en) Il-17f-specific capture agents, compositions, and methods of using and making
DK3558351T3 (da) Kombinationsvaccine til svin
EP3364945C0 (en) SOLID FORMULATION
EP3398588A4 (en) FORM-PREPARED PREPARATION
EP3560512A4 (en) COMPOSITION OF VACCINE AGAINST ZONA
EP3528839C0 (en) EXPEC GLYCOCONJUGATE VACCINE FORMULATIONS
IL254783A0 (en) Anthelmintic combinations and methods of use thereof
BR112016018371A2 (pt) derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo
IL251101A0 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
IL282753A (en) Immunogenic composition